TORONTO (October 17, 2018) – Cannabis (also referred to as marijuana) has been available by prescription for a number of years in Canada, but with broader legalization, more interest has been raised on the subject.Read More
All media inquiries can be directed to Jennifer Stranges, Associate, Corporate Communications at email@example.com or by calling 1-800-378-2233 ext. 290.
TORONTO (October 4 , 2018) – Today, the Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that the cost of cystic fibrosis (CF) drug ORKAMBI not be covered by provincial drug programs. Cystic Fibrosis Canada wholeheartedly disagrees with the decision and cautions that this could have deadly consequences for some Canadians with CF for years to come.Read More
TORONTO (June 19, 2018) – Cystic Fibrosis Canada national partner, CARSTAR, will fund travel and accommodations for participants of the Cystic Fibrosis Individualized Therapy (CFIT) study. With CARSTAR’s generous support, participants with cystic fibrosis (CF) from across Canada will travel to The Hospital for Sick Children in Toronto (SickKids) to take part in the ground-breaking study.Read More
TORONTO (June 12, 2018) – Cystic Fibrosis Canada is pleased to announce its national partnership with Canadian based jewelry company, NOGU. Mario and Luca Lavorato, founders of NOGU and both diagnosed with cystic fibrosis (CF) at birth, have pledged to donate 50 percent of gross sales from the company’s Kite Collection to Cystic Fibrosis Canada.Read More
TORONTO (June 1, 2018) – Cystic Fibrosis Canada’s largest fundraising event, The Walk to Make Cystic Fibrosis History, will go to new heights in 2019 with a trek to Machu Picchu in Peru. The week long journey begins on May 25, 2019 and is organized through Charity Challenge, the world's leading tour operator, running overseas fundraising challenges.Read More
May 2, 2018 (TORONTO) – Cystic Fibrosis Canada (CF Canada) is launching a national campaign this May, Cystic Fibrosis Awareness Month, to call on the government to make life-changing medications accessible for those who need it. Currently, a life-changing medication called Orkambi has the potential to benefit 2,100 of the 4,200 Canadians who live with cystic fibrosis (CF). Unfortunately, without public funding, many people with CF cannot access it despite its approval by Health Canada and doctors prescribing it.
TORONTO (April 24, 2018) — Cystic Fibrosis Canada’s (CF Canada) Board of Directors is pleased to announce the appointment of Kelly Grover to the position of President and Chief Executive Officer (CEO) effective June 4, 2018.Read More
Cystic Fibrosis Canada (Quebec) calls on government to help protect the health of people living with this fatal disease.
April 23, 2018 (Montreal, QC) – Cystic Fibrosis Canada is urging the Quebec government to take action to protect the health of Quebecers living with cystic fibrosis by granting them access to the life-changing medication Orkambi.Read More
Toronto, ON (November 14, 2017) – Cystic Fibrosis Canada is extremely disappointed that provincial governments have decided not to negotiate the price of Kalydeco, an effective cystic fibrosis (CF) medication, for Canadians with CF who have specific mutations and could potentially benefit from this drug.Read More
TORONTO (October 16, 2017) — Cystic Fibrosis Canada’s (CF Canada) Board of Directors has announced that Jeffrey Beach, Chief Executive Director, and Jennifer Nebesky, Chief Marketing and Communications Officer, will lead the organization as Co-Interim Chief Executive Officers (CEOs). Their tenure will begin on November 6, 2017 following the departure of current CEO Norma Beauchamp. Jeffrey will oversee the regional activities of both staff and volunteers, and Jennifer will oversee the teams at the national office.